100 Clinical Results associated with KRAS G12D Inhibitor(InventisBio)
Login to view more data
100 Translational Medicine associated with KRAS G12D Inhibitor(InventisBio)
Login to view more data
100 Patents (Medical) associated with KRAS G12D Inhibitor(InventisBio)
Login to view more data
1
Literatures (Medical) associated with KRAS G12D Inhibitor(InventisBio)
01 Jul 2024·CANCER CELL
HRS-4642: The next piece of the puzzle to keep KRAS in check
Article
Author: Drosten, Matthias ; Flores-Gómez, Alejandra A
KRASG12D is the most frequent KRAS mutation in human cancer. In this issue, Zhou et al. describe a novel KRASG12D inhibitor, HRS-4642, that shows potent and selective anti-tumor activity across various models and synergizes with proteasome inhibitors. Responses have also been observed in patients during an ongoing phase 1 trial.
100 Deals associated with KRAS G12D Inhibitor(InventisBio)
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.